REGN

Regeneron Pharmaceuticals에 대한 매도 수량은 투자자에게 Regeneron Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Regeneron Pharmaceuticals (NASDAQ:REGN) 주식, 공매도 수량 보고

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Large Cap

News

Movers

Trading Ideas

AFRM

FCNCA

KNTK

MEDP

MMYT

SMCI

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주가는 씨티그룹이 주식을 매수에서 중립으로 하향 조정했으나 목표 주가를 19달러에서 23달러로 상향 조정한 후 14.37% 하락했다.

리제네론과 슈퍼 마이크로는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 23일-9월 27일)

Biotech

Contracts

After-Hours Center

FGEN

피브로젠(NASDAQ:FGEN)의 주가는 회사가 미국 식품의약국(FDA)이 FG-3165에 대한 임상시험용 신약(IND)을 승인했다고 발표한 후 월요일 시간외 세션에서 급등했다. 이 회사는 또한 리제네론(NASDAQ:REGN)과 새로운 임상시험 공급 계약을 발표했다. 사건의 전말 (What Happened): 피브로젠은 월요일 시장 마감 후 FDA가 FG-3165의 IND를 승인하여 회사가 1상 임상 시험을 시작할 수 있게 되었다고 말했다.

피브로젠: 미 FDA의 임상시험용 신약 승인 발표 후 주가 급등

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 14.37% last week after Citigroup downgraded the stock from <a href="https://www.benzinga.com/quote/smmt/analyst-ratings" target="_blank" rel="noreferrer noopener">Buy to Neutral</a> but raised its price target from $19 to $23.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) stock plummeted 12.46%.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock fell 9.37% after Jefferies downgraded the stock from Buy to Hold and <a href="https://www.benzinga.com/quote/medp/analyst-ratings" target="_blank" rel="noreferrer noopener">cut its price target from $415 to $345</a>.</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) stock lost 8.94% last week after Leerink Partners <a href="https://www.benzinga.com/quote/regn/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded it</a> from Outperform to Market Perform and lowered its price target from $1,175 to $1,077.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares dived 8.74% after the company guided <a href="https://www.benzinga.com/pressreleases/24/09/b41024786/global-payments-shares-updated-strategy-and-medium-term-outlook-at-investor-conference" target="_blank" rel="noreferrer noopener">FY25 EPS growth below estimates</a>, and multiple firms downgraded the stock and<a href="https://www.benzinga.com/quote/gpn/analyst-ratings" target="_blank" rel="noreferrer noopener"> cut their respective price targets</a>.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock lost 8.39% last week. There was no company-specific news to justify the price loss.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares dipped 8.21% following a report indicating the company is being probed by the Department of Justice following an August short <a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener">report from</a><a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener"> Hindenburg Research</a>.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 6.10% amid reports suggesting Saudi Arabia may raise crude oil output.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) stock lost 6.09% last week after Wedbush analyst <a href="https://www.benzinga.com/quote/fcnca/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a> from Outperform to Neutral and lowered the price target from $2,450 to $2,150.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock fell 5.93% from pressure following the DOJ&#8217;s Carahsoft investigation.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41082440/chinese-stocks-dominate-jd-com-and-temu-parent-pdd-are-among-top-10-large-cap-gainers-last-week-se" target="_blank" rel="noreferrer noopener">Chinese Stocks Dominate &#8211; JD.com And Temu Parent PDD Are Among Top 10 Large Cap Gainers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41067118/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-with-copd" rel="noreferrer noopener">eosinophilic phenotype</a>, generally known as &#8220;smoker&#8217;s lung.&#8221;
Dupixent is the first biologic medicine approved in the U.S. to treat these patients.&nbsp;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease</a>.
The FDA approval is based on data from two Phase 3 trials (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=7kKUkEN_j7dfFFaJgSlNFzKZoO4mFwp3ozmSi0rwdtS0dUmDMMLRg3ML03GEfgLzJP_Yg33hoRBP-3IabEFUjTEGB_rbTRFqm_JL_llzjsfHVLX2ednnpkFojo7lpUCTxdCo_2YiyMr0ctlswWAwXOheTav4f6f3NjyHRNKi9AkNKqyHtmSD_t9WycxSdyDJF-7MluPxoOJfAy9kkVjGMA==" rel="noreferrer noopener">BOREAS</a> and&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=6PGgHroz2kXLk3EuPbMe_MIJ-5vFWDjqk9axy8qZd2P7xQ3L3g2ASjHZ8xt1uzCTdZuMSDrpF3jIDhOGYYWxNY22Nyhv04bkd8VwfNHxSVov8kQjYXAerk1eaKGoDXJDxNmLd9JxB76ojM5ft65Yy_p10fVEAMfMBBDCl7C-sv2-eIX7C8dxYBsnfHK7AYcbsomWIUjlfALjFhRk2bqT3w==" rel="noreferrer noopener">NOTUS</a>) that evaluated the efficacy and safety of Dupixent compared to placebo in adults currently on maximal standard-of-care inhaled therapy (nearly all on triple therapy).
<ul>
<li>Patients who received Dupixent in BOREAS (n=468) and NOTUS (n=470) experienced the following outcomes, respectively, compared to placebo (BOREAS n=471; NOTUS n=465):</li>
<li>The primary endpoint is a 30% and 34% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks.</li>
<li>74mL and 68mL numerically greater improvements in post-bronchodilator FEV1 from baseline at week 12 compared to placebo, sustained at 52 weeks. Statistically significant improvements of similar magnitude were observed in pre-bronchodilator FEV1 from baseline at 12 and 52 weeks, a key secondary endpoint.</li>
<li>51% response in a health-related quality of life measure in both trials compared to 43% and 47% with placebo at 52 weeks.</li>
</ul>
About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy.
In the U.S., approximately 300,000 people live with inadequately controlled COPD and an eosinophilic phenotype.
Patients with an eosinophilic phenotype contribute to a ~30% increase in exacerbations and an increased risk of COPD-related re-hospitalizations within a year.
Today, China&#8217;s National Medical Products Administration also approved Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41063987/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic" rel="noreferrer noopener">raised blood eosinophils</a>.
The approval is based on BOREAS and NOTUS Phase 3 trial results.
Price Action:&nbsp;At last check Friday, REGN stock was up 2.86% at $1,069.75, and SNY stock was up 1.49% at $57.85.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41067826/federal-investigations-continue-for-psychiatric-hospital-chain-operator-acadia-healthcare-even-aft" target="_blank" rel="noreferrer noopener">Federal Investigations Continue For Psychiatric Hospital Chain Operator Acadia Healthcare Even After $20M Settlement Over False Claims Allegations</a>.</li>
</ul>

Health Care

General

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

Dupixent is indicated&nbsp;for the approximately 300,000 adults in the U.S. with inadequately controlled&nbsp;chronic obstructive pulmonary disease (COPD)&nbsp;and&nbsp;an eosinophilic phenotype &nbsp;
Following recent&nbsp;approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo
Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the U.S.
TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the U.S. to treat these patients.&nbsp;&nbsp;

Global

Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life. 
&nbsp;
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government&#39;s Healthy China 2030 public health plan.
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.

Regeneron Pharmaceuticals And Sanofi Today Announced That  National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/25/final-trades-trane-tech-american-tower-regeneron-and-taiwan-semi.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/government/24/09/41007184/taiwan-semi-secures-7-5b-boost-for-arizona-expansion-aims-for-advanced-chip-production-report">cheap</a>.
On Monday, Taiwan Semiconductor Manufacturing bagged the government's approval for an additional $7.5 billion infusion into Taiwan Semiconductor Arizona unit, the Taipei Times cited the Department of Investment Review statement.
Amy Raskin of Chevy Chase Trust named Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals' effort to prevent the sale of Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals <a href="https://www.benzinga.com/general/biotech/24/09/41012464/why-is-regeneron-pharmaceuticals-stock-trading-lower-on-tuesday">for the Federal Circuit</a>.
 Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management picked American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) as her final trade.
On Sept. 23, JP Morgan analyst Philip Cusick maintained American Tower with an Overweight rating and raised the price target from $240 to $250.
Joseph M. Terranova of Virtus Investment Partners named Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>).
On July 31, Trane Technologies reported better-than-expected second-quarter financial results and raised its FY24 guidance. Revenues grew 13% Y/Y to $5.31 billion, surpassing the consensus of $5.13 billion. Bookings increased 19% Y/Y to$5.34 billion in the quarter. Adjusted EPS of $3.30 surpassed the street view of $3.08.
Price Action:
<ul>
<li>Taiwan Semiconductor gained 0.2% to close at $182.35 during Wednesday's session.</li>
<li>Regeneron Pharmaceuticals shares fell 1.4% to settle at $1,031.15 on Wednesday.</li>
<li>American Tower fell 0.4% to close at $235.63 during Wednesday's session.</li>
<li>Trane Technologies shares gained 1% to close at $387.70 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

AMGN

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'

Analyst Ratings

CNBC Halftime Report Final Trades: Trane Technologies, American Tower, Regeneron Pharmaceuticals, Taiwan Semiconductor Manufacturing

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $445,523, and 2 were calls, valued at $67,950.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1170.0 for Regeneron Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $750.0 to $1170.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727279127_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$30.7</td>
<td>$26.7</td>
<td>$30.7</td>
<td>$1040.00</td>
<td>$122.8K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">41</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$46.5</td>
<td>$41.0</td>
<td>$44.6</td>
<td>$1000.00</td>
<td>$44.6K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$144.0</td>
<td>$137.5</td>
<td>$139.66</td>
<td>$1170.00</td>
<td>$41.8K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$97.0</td>
<td>$96.9</td>
<td>$97.0</td>
<td>$1120.00</td>
<td>$38.8K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$100.7</td>
<td>$94.6</td>
<td>$96.6</td>
<td>$1120.00</td>
<td>$38.6K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">29</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Current Position of Regeneron Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 389,940, the REGN's price is down by -1.07%, now at $1034.78. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 36 days.</li>
</ul>
<h3>Expert Opinions on Regeneron Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1184.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $1282. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $1015. 
&#x2A; An analyst from Leerink Partners downgraded its action to Market Perform with a price target of $1077. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1250. 
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $1300. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Regeneron Pharmaceuticals Background</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>27.69</td>
<td>4.09</td>
<td>8.87</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>AbbVie Inc</td>
<td>64.72</td>
<td>50.43</td>
<td>6.24</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>57.07</td>
<td>30.02</td>
<td>5.78</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>102.20</td>
<td>5.71</td>
<td>3.77</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>24.48</td>
<td>1.78</td>
<td>2.93</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>16.45</td>
<td>2.80</td>
<td>6.73</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>19.02</td>
<td>3.29</td>
<td>5.54</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>52.64</td>
<td>2.50</td>
<td>5.22</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>155.37</td>
<td>4.09</td>
<td>3.70</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>167.40</td>
<td>11.12</td>
<td>8.15</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>35.09</td>
<td>4.69</td>
<td>5.65</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.04</td>
<td>1.59</td>
<td>61.73</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>22.66</td>
<td>3.54</td>
<td>4.02</td>
<td>10.65%</td>
<td>$0.28</td>
<td>$0.62</td>
<td>35.61%</td>
</tr>
<tr>
<td>Average</td>
<td>59.93</td>
<td>10.13</td>
<td>9.96</td>
<td>5.11%</td>
<td>$1.23</td>
<td>$2.64</td>
<td>30.7%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By closely studying Regeneron Pharmaceuticals, we can observe the following trends: 
<ul>
<li>
At 27.69, the stock's Price to Earnings ratio is 0.46x less than the industry average, suggesting favorable growth potential.
</li>
<li>
Considering a Price to Book ratio of 4.09, which is well below the industry average by 0.4x, the stock may be undervalued based on its book value compared to its peers.
</li>
<li>
The Price to Sales ratio is 8.87, which is 0.89x the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
With a Return on Equity (ROE) of 5.19% that is 0.08% above the industry average, it appears that the company exhibits efficient use of equity to generate profits.
</li>
<li>
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.76 Billion, which is 1.43x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
The company has higher gross profit of $3.07 Billion, which indicates 1.16x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 12.32% compared to the industry average of 30.7%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727276422_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Regeneron Pharmaceuticals can be assessed by comparing it to its top 4 peers, resulting in the following observations:
<ul>
<li>
Regeneron Pharmaceuticals has a stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.1.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be perceived as a positive indicator by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Regeneron Pharmaceuticals, the PE, PB, and PS ratios are all low compared to industry peers, indicating potential undervaluation. On the other hand, the high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency. However, the low revenue growth may raise concerns about future performance relative to competitors in the Biotechnology industry.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology

In an investor update on Tuesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.
Amgen <a target="_blank" href="https://investors.amgen.com/static-files/a7119a35-06de-497e-ba75-146404c54d95" rel="noreferrer noopener">reported</a> that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.
<ul>
<li>32.8% of rocatinlimab-treated subjects achieved an EASI-75 response at week 24 vs. 13.7% placebo.</li>
<li>19.3% of rocatinlimab-treated subjects achieved a vIGA-AD 0/1 response at week 24 vs. 6.6% placebo.</li>
<li>16.4% of rocatinlimab-treated subjects achieved a rIGA 0/1 response at week 24 vs. 4.9% placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u" rel="noreferrer noopener">Amgen&#8217;s Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts</a>.
MINT Phase 3 trial of Uplizna in generalized myasthenia gravis showed a clinically meaningful and statistically significant MG-ADL (Myasthenia Gravis Activities of Daily Living) score, a measure of the severity of myasthenia gravis symptoms.
After two doses of Uplizna, MG-ADL score showed an overall improvement of -4.2, versus -1.9 placebo adjusted.
The trial demonstrated a statistically significant improvement in the Quantitative Myasthenia Gravis (QMG) score, a clinical assessment that measures the severity of myasthenia gravis.
QMG score improvement with Uplizna compared to placebo at week 26 was -4.8 overall improvement compared to -2.5 placebo adjusted.
No new safety signals were identified.
STAT News <a target="_blank" href="https://www.statnews.com/2024/09/24/amgen-success-trials-eczema-rocatinlimab-myasthenia-gravis-uplizna-competition-remains-stiff/" rel="noreferrer noopener">noted</a> that though the trials succeeded, the therapies did not beat existing competitors on the market.
51% of adults <a target="_blank" href="https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/easi-clinical-trial" rel="noreferrer noopener">treated</a> with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/ Regeneraon Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) achieved EASI-75 vs.&nbsp;15%&nbsp;with placebo at Week 16 in SOLO 1 trial and 44% vs. 12% in SOLO 2 trial.
William Blair noted that rocatinlimab&#8217;s data fell short of expectations, raising concerns about how its clinical profile stacks up in the increasingly competitive atopic dermatitis market, particularly as the broader ROCKET program unfolds.
On the other hand, the Uplizna results for myasthenia gravis exceeded William Blair&#8217;s expectations, indicating a strong market potential for the treatment. Key advantages include its less frequent dosing and potential to reduce steroid use.
The focus will be determining Uplizna&#8217;s position within the myasthenia gravis treatment landscape alongside other options like FcRn, IVIg, complement inhibitors, rituximab, and more. Additionally, the potential for Uplizna&#8217;s CD19-targeting strategy in autoimmune diseases will be closely watched, especially with competitors like Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>).
Price Action: AMGN stock is trading lower by 2.09% to $324.04 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff" target="_blank" rel="noreferrer noopener">Private Equity Firms Circle Sanofi&#8217;s Consumer Health Business Amid Potential Spinoff</a>.</li>
</ul>
Photo via Shutterstock

Analyst Color

CGEM

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Chief District Judge Thomas Kleeh <a href="https://www.courtlistener.com/docket/68435952/in-re-aflibercept-patent-litigation/?filed_after=&amp;filed_before=&amp;entry_gte=&amp;entry_lte=&amp;order_by=desc#entry-343">denied</a> Regeneron Pharmaceuticals, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) effort to prevent the sale of Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Eylea biosimilar.
Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit.
The <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/InReAfliberceptPatentLitigationDocketNo124md03103NDWVaApr112024Co/9?doc_id=X5Q74042K7G9TGAR2GDOLU0DNF6" rel="noreferrer noopener">appeal </a>is from the Order issued on September 23, 2024, which denied Regeneron&#8217;s request for a preliminary injunction, along with any related orders, decisions, rulings, findings, or conclusions connected to that Order.
Reuters highlighted that an Amgen spokesperson expressed the company&#8217;s satisfaction with the decision. Amgen will reveal the timeline for launching its biosimilar Pavblu &#8220;in due course.&#8221;
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea. The lawsuit claims the infringement of over 30 patents, which the pharma claims will &#8220;irreparably&#8221; harm its business if Amgen is not &#8220;enjoined&#8221; from violating these protections.
The lawsuit also <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/egpbakxeavq/REGENERON%20AMGEN%20LAWSUIT%20complaint.pdf" rel="noreferrer noopener">notes</a>, &#8220;Amgen&#8217;s commercial manufacture, use, offer for sale, and/or sale within the United States, or importation into the United States, of ABP 938 before the expiration of the '106 patent will cause Regeneron injury, entitling Regeneron to damages and/or other monetary relief.&#8221;
In October 2023, Amgen said the FDA <a target="_blank" href="https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-financial-results" rel="noreferrer noopener">accepted</a> its abbreviated Biologics Drug Application for ABP 938, a biosimilar copy of Eylea.
Stat News <a target="_blank" href="https://www.statnews.com/2024/09/24/regeneron-eylea-biosimilar-amgen-fight-heats-up/" rel="noreferrer noopener">noted</a> that the judge&#8217;s decision came as a surprise, given that this same judge had previously approved Regeneron&#8217;s requests for injunctions against other pharmaceutical companies attempting to release Eylea biosimilars.
In December, a court ruling found that Viatris Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) replica of Regeneron&#8217;s Eylea <a href="https://www.benzinga.com/general/biotech/23/12/36408741/regeneron-celebrates-legal-win-court-upholds-eylea-medication-patent" target="_blank" rel="noreferrer noopener">violated patent rights</a>.
Price Action: REGN stock is down 6% at $1,025.44 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41010674/diamondback-energy-kinetik-strengthen-stake-in-epic-crude-with-new-deal-and-long-term-commitment" target="_blank" rel="noreferrer noopener">Diamondback Energy, Kinetik Strengthen Stake In EPIC Crude With New Deal And Long-Term Commitments</a>.</li>
</ul>

Legal

VTRS

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1282 to $1252.

Price Target

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1252

BMO Capital analyst Evan David Seigerman reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and maintains $1300 price target.

Reiteration

BMO Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1300 Price Target

WIIM

Regeneron Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $1175 to $1077.

Truist Securities analyst Srikripa Devarakonda reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and maintains $1200 price target.

Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://widgets.benzinga.com/analyst-stock-ratings/analyst/60f00f67c9514d0001c5b305/charlene-liu">HSBC analyst Charlene Liu</a> downgraded the rating for Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Buy to Hold and announced a price target of $100. Baidu shares gained 2.4% to close at $88.28 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other </a><a href="https://www.benzinga.com/quote/bidu/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
<li>Redburn Atlantic analyst Peter Low downgraded the rating for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Buy to Neutral. BP shares gained 0.7% to close at $32.86 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this </a><a href="https://www.benzinga.com/quote/BP/analyst-ratings">stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell </a>downgraded McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Outperform to Neutral and lowered the price target from $603 to $531. McKesson shares fell 0.6% to close at $505.00 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/MCK/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Andrew Berens downgraded the rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Outperform to Market Perform, while cutting the price target from $1,175 to $1,077. Regeneron Pharmaceuticals shares fell 4.6% to close at $1,091.98 on Monday. <a href="https://www.benzinga.com/quote/REGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59c264af6e84a70001eb1bb8/david-chiaverini">Wedbush analyst David Chiaverini </a>downgraded First Horizon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) from Outperform to Neutral and slashed the price target from $20 to $17. First Horizon shares fell 1.9% to close at $15.67 on Monday. <a href="https://www.benzinga.com/quote/FHN/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
</ul>
Considering buying BP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/c9689ca0-032e-42a9-818e-8c799d42f940" alt="" style="width:618px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Downgrades

Pre-Market Outlook

BIDU

This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Leerink Partners analyst Andrew Berens downgrades Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Outperform to Market Perform and lowers the price target from $1175 to $1077.

Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform, Lowers Price Target to $1077

Wells Fargo analyst Mohit Bansal reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and maintains $1200 price target.

Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) revealed 18 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $409,131, and 10 were calls, valued at $419,774.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $700.0 to $1620.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 51.43 with a total volume of 748.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $700.0 to $1620.0 over the last 30 days.
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727110873_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$19.1</td>
<td>$19.0</td>
<td>$19.0</td>
<td>$1120.00</td>
<td>$161.5K</td>
<td style="text-align: right;">20</td>
<td style="text-align: right;">115</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$29.8</td>
<td>$27.5</td>
<td>$27.5</td>
<td>$1130.00</td>
<td>$82.5K</td>
<td style="text-align: right;">252</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$1130.00</td>
<td>$66.2K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">111</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$515.0</td>
<td>$505.0</td>
<td>$515.0</td>
<td>$1620.00</td>
<td>$51.5K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$20.5</td>
<td>$17.1</td>
<td>$20.5</td>
<td>$1125.00</td>
<td>$47.1K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">23</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Regeneron Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a trading volume of 249,496, the price of REGN is down by -3.02%, reaching $1110.5.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Regeneron Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1168.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $1282. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $1282. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $1250. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $1015. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $1015. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In REGN Options

The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1 Year Of Age

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and maintains $1282 price target.

RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1282 Price Target

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of $1,245.00. Akash T...

Regeneron's Patent Resilience and Market Positioning Justify a Buy Rating

Amgen stock slides 5% as analysts weigh in on drug study results

Amgen stock slides 5% as analysts weigh in on drug study results (update)

Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case

Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case

Sanofi, Regeneron get additional Chinese approval for Dupixent

Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD

Notable analyst calls this week: Microsoft, Starbucks and GM among top picks

Regeneron: Long-Term Defensive Investment

Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales

ABBV

ARGX

BMBL

BNTX

MSFT

NTLA

RACE

RIVN

SBUX

SNYNF

TSLA

ZLAB

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Press Releases

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Small Cap

Opinion

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Comments

Regeneron Pharmaceuticals

매도 수량

Regeneron Pharmaceuticals (NASDAQ:REGN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌